CCNJ抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: K562 cell lysate, Primary antibody: P06317(CCNJ Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P06317(CCNJ Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The CCNJ antibody targets Cyclin J, a member of the cyclin protein family involved in regulating cell cycle progression. Cyclins function by binding and activating cyclin-dependent kinases (CDKs), which drive transitions between cell cycle phases. While cyclins like Cyclin D and Cyclin E are well-characterized, Cyclin J (encoded by the CCNJ gene) remains less understood. It is evolutionarily conserved and expressed in various tissues, with studies suggesting roles in developmental processes, DNA damage response, and transcriptional regulation. In Drosophila, Cyclin J is critical for oogenesis and embryogenesis, while mammalian research links it to cell proliferation and differentiation, particularly in germ cells and certain cancers.

CCNJ antibodies are vital tools for investigating Cyclin J's expression, localization, and function. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research using these antibodies has revealed Cyclin J's potential involvement in tumorigenesis, with altered expression observed in malignancies such as hepatocellular carcinoma and glioblastoma. Additionally, studies explore its interaction with CDKs and other cell cycle regulators, offering insights into its mechanistic contributions. Despite progress, further work is needed to clarify its precise molecular pathways and therapeutic relevance. CCNJ antibodies thus serve as essential reagents for advancing cell cycle biology and disease-related research.